Aroda VR, et al. - In patients with type 2 diabetes, researchers studied insulin degludec plus liraglutide (IDegLira) vs insulin glargine 100 units/mL (IGlar U100) for durability using a visit schedule that mirrored routine clinical practice in this 104-week international, multicenter, open-label, phase 3b randomized controlled trial. In patients with uncontrolled type 2 diabetes on oral antidiabetic medicines, initial injectable therapy with IDegLira vs IGlar U100 led to less patients achieving the treatment intensification criterion over 104 weeks, with longer durability of the treatment impact. No new or unexpected safety and tolerability issues were identified, and no therapeutic deaths occurred.